Editing Baker Pharmaceuticals
Warning: You are not logged in. Your IP address will be publicly visible if you make any edits. If you log in or create an account, your edits will be attributed to your username, along with other benefits.
The edit can be undone.
Please check the comparison below to verify that this is what you want to do, and then save the changes below to finish undoing the edit.
Latest revision
Your text
Line 4:
Line 4: | Dissolved = | Dissolved = | Previous Names = | Previous Names = − | headquarters = New Benner<br/>([[Baker 3]])<ref name=HSTLC-142/> + | headquarters = New Benner<br/>([[Baker 3]])<ref name=HSTLC-144/> | leadership = [[CEO of Baker Pharmaceuticals|CEO]] | leadership = [[CEO of Baker Pharmaceuticals|CEO]] | products = | products = Line 10:
Line 10: | Division = | Division = }} }} − '''Baker Pharmaceuticals''' was a pharmaceutical company in the [[Lyran Commonwealth]], with its assets eventually acquired by the mammoth [[Nashan Diversified]]. <ref name=HSTLC-142>''House Steiner (The Lyran Commonwealth)'', p. 142 "Socioeconomics - Other Major Commonwealth Industries - Baker Pharmaceuticals"</ref> <ref name=HHS-134>''Handbook: House Steiner'', p. 134 - "Economics - Major Industries- Nashan Diversified".</ref> + '''Baker Pharmaceuticals''' was a pharmaceutical company in the [[Lyran Commonwealth]], with its assets eventually acquired by the mammoth [[Nashan Diversified]]. <ref name=HSTLC-144>''House Steiner (The Lyran Commonwealth)'', p. 144 "Socioeconomics - Other Major Commonwealth Industries - Baker Pharmaceuticals"</ref> <ref name=HHS-134>''Handbook: House Steiner'', p. 134 - "Economics - Major Industries- Nashan Diversified".</ref> ==Company Profile== ==Company Profile== − '''Commonwealth Stock Exchange Symbol:''' BakPhar. <ref name=HSTLC-142/> + '''Commonwealth Stock Exchange Symbol:''' BakPhar. <ref name=HSTLC-144/> − '''President/CEO:''' [[John Sleeth]] (circa 3024).<ref name=HSTLC-142/> + '''President/CEO:''' John Sleeth (circa 3024).<ref name=HSTLC-144/> ==Overview== ==Overview== − Baker Pharmaceuticals had been in business with the Lyran Commonwealth for many years but encountered serious financial and personnel problems after losing a 300-million-[[Kroner|S-Bill]] lawsuit in [[3023]] when a batch of their synthetic molecular antibodies went toxic, killing over 100 [[Lyran Commonwealth Armed Forces]] soldiers. Like a shark smelling blood in the water, Nashan Diversified launched a takeover attempt in [[3024]], which Baker CEO John Sleeth attempted to resist by ordering his brokers to buy back all public Baker stocks at a substantially higher price than Nashan's offer.<ref name=HSTLC-142/> + Baker Pharmaceuticals had been in business with the Lyran Commonwealth for many years but encountered serious financial and personnel problems after losing a 300-million-[[Kroner|S-Bill]] lawsuit in [[3023]] when a batch of their synthetic molecular antibodies went toxic, killing over 100 [[Lyran Commonwealth Armed Forces]] soldiers. Like a shark smelling blood in the water, Nashan Diversified launched a takeover attempt in [[3024]], which Baker CEO John Sleeth attempted to resist by ordering his brokers to buy back all public Baker stocks at a substantially higher price than Nashan's offer.<ref name=HSTLC-144/> − While saving the company in the short-term, the heavy financial burden of the buy-back forced BP to cut costs and let go staff, leaving it in dire straits with many observers questioning if the company would survive beyond [[3025]].<ref name=HSTLC-142/> Nashan would ultimately succeed in acquiring Baker Pharmaceuticals, but rather than reorganize and integrate the company's Baker 3 headquarters into the Nashan family, Nashan chose to virtually liquidate BP and transfer its remaining assets to Nashan's newer [[Donegal]] offices to serve as its '''Nashan Pharmaceuticals''' division.<ref name=HHS-134/> + While saving the company in the short-term, the heavy financial burden of the buy-back forced BP to cut costs and let go staff, leaving it in dire straits with many observers questioning if the company would survive beyond [[3025]].<ref name=HSTLC-144/> Nashan would ultimately succeed in acquiring Baker Pharmaceuticals, but rather than reorganize and integrate the company's Baker 3 headquarters into the Nashan family, Nashan chose to virtually liquidate BP and transfer its remaining assets to Nashan's newer [[Donegal]] offices to serve as its '''Nashan Pharmaceuticals''' division.<ref name=HHS-134/> ==References== ==References==
The edit can be undone. Please check the comparison below to verify that this is what you want to do, and then save the changes below to finish undoing the edit.
| Latest revision | Your text | ||
| Line 4: | Line 4: | ||
| Dissolved = | | Dissolved = | ||
| Previous Names = | | Previous Names = | ||
| − | | headquarters = New Benner<br/>([[Baker 3]])<ref name=HSTLC- | + | | headquarters = New Benner<br/>([[Baker 3]])<ref name=HSTLC-144/> |
| leadership = [[CEO of Baker Pharmaceuticals|CEO]] | | leadership = [[CEO of Baker Pharmaceuticals|CEO]] | ||
| products = | | products = | ||
| Line 10: | Line 10: | ||
| Division = | | Division = | ||
}} | }} | ||
| − | '''Baker Pharmaceuticals''' was a pharmaceutical company in the [[Lyran Commonwealth]], with its assets eventually acquired by the mammoth [[Nashan Diversified]]. <ref name=HSTLC- | + | '''Baker Pharmaceuticals''' was a pharmaceutical company in the [[Lyran Commonwealth]], with its assets eventually acquired by the mammoth [[Nashan Diversified]]. <ref name=HSTLC-144>''House Steiner (The Lyran Commonwealth)'', p. 144 "Socioeconomics - Other Major Commonwealth Industries - Baker Pharmaceuticals"</ref> <ref name=HHS-134>''Handbook: House Steiner'', p. 134 - "Economics - Major Industries- Nashan Diversified".</ref> |
==Company Profile== | ==Company Profile== | ||
| − | '''Commonwealth Stock Exchange Symbol:''' BakPhar. <ref name=HSTLC- | + | '''Commonwealth Stock Exchange Symbol:''' BakPhar. <ref name=HSTLC-144/> |
| − | '''President/CEO:''' | + | '''President/CEO:''' John Sleeth (circa 3024).<ref name=HSTLC-144/> |
==Overview== | ==Overview== | ||
| − | Baker Pharmaceuticals had been in business with the Lyran Commonwealth for many years but encountered serious financial and personnel problems after losing a 300-million-[[Kroner|S-Bill]] lawsuit in [[3023]] when a batch of their synthetic molecular antibodies went toxic, killing over 100 [[Lyran Commonwealth Armed Forces]] soldiers. Like a shark smelling blood in the water, Nashan Diversified launched a takeover attempt in [[3024]], which Baker CEO John Sleeth attempted to resist by ordering his brokers to buy back all public Baker stocks at a substantially higher price than Nashan's offer.<ref name=HSTLC- | + | Baker Pharmaceuticals had been in business with the Lyran Commonwealth for many years but encountered serious financial and personnel problems after losing a 300-million-[[Kroner|S-Bill]] lawsuit in [[3023]] when a batch of their synthetic molecular antibodies went toxic, killing over 100 [[Lyran Commonwealth Armed Forces]] soldiers. Like a shark smelling blood in the water, Nashan Diversified launched a takeover attempt in [[3024]], which Baker CEO John Sleeth attempted to resist by ordering his brokers to buy back all public Baker stocks at a substantially higher price than Nashan's offer.<ref name=HSTLC-144/> |
| − | While saving the company in the short-term, the heavy financial burden of the buy-back forced BP to cut costs and let go staff, leaving it in dire straits with many observers questioning if the company would survive beyond [[3025]].<ref name=HSTLC- | + | While saving the company in the short-term, the heavy financial burden of the buy-back forced BP to cut costs and let go staff, leaving it in dire straits with many observers questioning if the company would survive beyond [[3025]].<ref name=HSTLC-144/> Nashan would ultimately succeed in acquiring Baker Pharmaceuticals, but rather than reorganize and integrate the company's Baker 3 headquarters into the Nashan family, Nashan chose to virtually liquidate BP and transfer its remaining assets to Nashan's newer [[Donegal]] offices to serve as its '''Nashan Pharmaceuticals''' division.<ref name=HHS-134/> |
==References== | ==References== | ||